← The SEC Ephemeris: the whole map
Alkermes, Inc. Lybalvi
In the graph: all 8 documents (201 pages).
- Application
- NDA 213378
- Ticker
- ALKS
- Product
- Lybalvi
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- November 13, 2020
From FDA letters and SEC filings. Not investment or medical advice.